Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41

Lake Street analyst Daniel Brims has initiated coverage on Kyntra Bio (NASDAQ: KYNB) with a Buy rating. The firm has set a price target of $41 for the stock.